<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">22782463</PMID>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1436-3305</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</Title>
<ISOAbbreviation>Gastric Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.</ArticleTitle>
<Pagination>
<MedlinePgn>175-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10120-012-0167-0</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese patients with mGC have been published to date. The AVAGAST (XP ± bevacizumab in mGC) and ToGA (XP ± trastuzumab in human epidermal growth factor receptor 2 [HER2]-positive mGC) studies were the first two global studies including Japanese mGC patients. The aim of this analysis was to investigate the efficacy and safety of XP in Japanese mGC patients, using AVAGAST and ToGA subgroup data.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies. There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2-positive tumors; therefore, efficacy was evaluated separately.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone. Median overall and progression-free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study. Overall response rates were 49.2 % in the AVAGAST and 58.5 % in the ToGA study. Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yamaguchi</LastName>
<ForeName>Kensei</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Saitama Cancer Center Hospital, 818 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan. k-yamaguchi@cancer-c.pref.saitama.jp</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sawaki</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doi</LastName>
<ForeName>Toshihiko</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Satoh</LastName>
<ForeName>Taroh</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yamada</LastName>
<ForeName>Yasuhide</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Omuro</LastName>
<ForeName>Yasushi</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishina</LastName>
<ForeName>Tomohiro</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boku</LastName>
<ForeName>Narikazu</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chin</LastName>
<ForeName>Keisho</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hamamoto</LastName>
<ForeName>Yasuo</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takiuchi</LastName>
<ForeName>Hiroya</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Komatsu</LastName>
<ForeName>Yoshito</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saji</LastName>
<ForeName>Shigehira</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koizumi</LastName>
<ForeName>Wasaburo</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miyata</LastName>
<ForeName>Yoshinori</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Atsushi</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baba</LastName>
<ForeName>Eishi</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tamura</LastName>
<ForeName>Takao</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abe</LastName>
<ForeName>Takashi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ohtsu</LastName>
<ForeName>Atsushi</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2012</Year>
<Month>07</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Japan</Country>
<MedlineTA>Gastric Cancer</MedlineTA>
<NlmUniqueID>100886238</NlmUniqueID>
<ISSNLinking>1436-3291</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0W860991D6</RegistryNumber>
<NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6804DJ8Z9U</RegistryNumber>
<NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U3P01618RT</RegistryNumber>
<NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Gastric Cancer. 2013 Apr;16(2):183-4</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D044466">Asian Continental Ancestry Group</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069287">Capecitabine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2012</Year>
<Month>03</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2012</Year>
<Month>05</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2012</Year>
<Month>7</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2012</Year>
<Month>7</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2013</Year>
<Month>11</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">22782463</ArticleId>
<ArticleId IdType="doi">10.1007/s10120-012-0167-0</ArticleId>
<ArticleId IdType="pmc">PMC3627028</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Clin Oncol. 2006 May 10;24(14):2188-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16682738</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Gastroenterol. 2006 Nov;101(11):2485-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17029617</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2008 Mar;9(3):215-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18282805</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Oct 20;29(30):3968-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21844504</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2010 Aug 28;376(9742):687-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20728210</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Gastroenterol. 2008;43(4):256-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18458840</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anticancer Drugs. 2008 Sep;19(8):819-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18690094</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2009 Sep;20(9):1529-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19474114</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2009 Nov;10(11):1063-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19818685</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2010 Jan 1;126(1):162-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19588501</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Toxicol Lett. 1998 Dec 28;102-103:227-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10022258</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>